局限性前列腺癌不采用治疗计划MRI的立体定向体部放疗安全性
单中心分析2006至2020年3410例接受SBRT的局限性前列腺癌患者,其中162例(4.75%)仅用CT制定治疗计划。CT组年龄更大、风险分级更高、CTV有增大趋势、总剂量更低且盆腔淋巴结放疗更频繁;CT组仅报告2例3级及以上毒性,1个月时泌尿和肠道评分下降、后续随访恢复基线,中位2.3年早期生化失败5例(Phoenix标准)。
要点
- 3410例接受SBRT的局限性前列腺癌中162例(4.75%)仅用CT制定治疗计划。
- CT组较MRI组年龄更大(69.9 vs 67.2,p<0.001)、风险分级和分级更高(p<0.001)。
- CT组仅报告2例3级及以上毒性,1个月泌尿和肠道评分下降后恢复基线,中位2.3年早期生化失败5例。
核心结论
- 尽管MRI组与CT组之间存在临床差异,CT组观察到可耐受的毒性特征,并得到EPIC问卷数据支持;在无法接受MRI的患者中,早期临床随访下总体临床结局似乎相当。
研究设计与样本
- 研究分析了2006年至2020年间在一家学术机构接受SBRT的3410例局限性前列腺癌患者。
- 急性和晚期毒性采用不良事件通用术语标准5.0版评估,EPIC问卷评估生活质量,并检测PSA最低值以发现生化失败。
主要发现
- 共有162例患者(4.75%)仅用CT制定治疗计划。
- CT组较MRI组年龄更大(69.9 vs 67.2,p<0.001),风险分级和分级更高(p<0.001)。
- CT组较MRI组CTV有增大趋势(82.56 cc vs 76.90 cc;p=0.055)、总放疗剂量更低(p=0.048)、盆腔淋巴结放疗更频繁(p<0.001)。
- CT组仅报告2例3级及以上毒性。
- CT组生活质量数据显示1个月时泌尿和肠道评分下降,后续随访恢复基线;中位2.3年早期生化失败数据显示5例失败(Phoenix标准)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of treatment planning prostate MRI for Stereotactic Body Radiation Therapy (SBRT) is largely a standard, yet not all patients can receive MRI for a variety of clinical reasons. Thus, we aim to investigate the safety of patients who received CT alone based SBRT planning for the definitive treatment of localized prostate cancer. METHODS: Our study analyzed 3410 patients with localized prostate cancer who were treated with SBRT at a single academic institution between 2006 and 2020. Acute and late toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 5.0. Expanded Prostate Cancer Index Composite (EPIC) questionnaires evaluated QOL and PSA nadir was evaluated to detect biochemical failures. RESULTS: A total of 162 patients (4.75%) received CT alone for treatment planning. The CT alone group was older relative to the MRI group (69.9 vs 67.2, p < 0.001) and had higher risk and grade disease (p < 0.001). Additionally, the CT group exhibited a trend in larger CTVs (82.56 cc vs 76.90 cc; p = 0.055), lower total radiation doses (p = 0.048), and more frequent pelvic nodal radiation versus the MRI group (p < 0.001). There were only two reported cases of Grade 3 + toxicity within the CT alone group. Quality of life data within the CT alone group revealed declines in urinary and bowel scores at one month with return to baseline at subsequent follow up. Early biochemical failure data at median time of 2.3 years revealed five failures by Phoenix definition. CONCLUSIONS: While clinical differences existed between the MRI and CT alone group, we observed tolerable toxicity profiles in the CT alone cohort, which was further supported by EPIC questionnaire data. The overall clinical outcomes appear comparable in patients unable to receive MRI for their SBRT treatment plan with early clinical follow up.
引用
- Amarell K, Jaysing A, Mendez C, et al. Safety of stereotactic body radiation therapy for localized prostate cancer without treatment planning MRI. Radiat Oncol. 2022. PMID: 35366926. doi:10.1186/s13014-022-02026-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。